Big Year For UCB As Bimzelx Awaits US Green Light
Psoriasis Approval Imminent After Delay
The Brussels-based company's head of immunology has told Scrip that going into a crowded market against several highly effective biologics across different classes holds no fears for UCB despite some concerns that US prescribers will stick to what they know when it comes to psoriasis therapies.
